Drug Combination Details
| General Information of the Combination (ID: C50739) | |||||
|---|---|---|---|---|---|
| Name | 3-O-acetylbetulin NP Info | + | SLC-0111 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Enhancement | DNA damage | ||||
| Enhancement | Radiosensitivity | |||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-231 | Breast cancer | Homo sapiens | ||||
| Experimental
Result(s) |
The combined treatment with 3-AC and CAI strongly enhanced radiosensitivity, increased cytotoxicity, inhibited cell motility and enhanced DNA damage. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells. Chem Biol Interact. 2021 Jan 5;333:109326. | |||
